comprehensive -WSS

comprehensive

author：leisure time 2025-09-06 03:17:15 - browse：472

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Report: NIH

WSS

David Sabatini, ex

Has Bernie Sanders reached the limit of his pharma bullying effort?

Biohaven protein

Welsh Carson private equity firm escapes from FTC antitrust case

Stigma and the return of syphilis

Chemotherapy before breast cancer surgery might fuel metastasis

focus

comprehensive

entertainment

Drug repurposing or repositioning? The language matters

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Activists slam private health insurers over coverage restrictions

Welsh Carson private equity firm escapes from FTC antitrust case

The high cost of giving birth even with insurance

As health system earnings go up, health insurance stocks go down

Moonlake's readout produced a cash windfall. Risks remain

David Sabatini, ex

Activists slam private health insurers over coverage restrictions

As health system earnings go up, health insurance stocks go down

leisure time

AltruBio raises $225 million to develop ulcerative colitis drug

Chemotherapy before breast cancer surgery might fuel metastasis

Akili, maker of video game for ADHD, to be acquired for 34 million

Deliver public health messages at the right time

Do more moles mean more problems? Not so, says new study

AltruBio raises $225 million to develop ulcerative colitis drug

hotspot

hotspot

leisure time

hotspot